NGM

About NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently undergoing Phase IIb clinical evaluation for non-alcoholic steatohepatitis (NASH). Another key asset, MK-3655, is an agonistic antibody designed to activate fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb trials for treating both type 2 diabetes and NASH. NGM's pipeline further encompasses NGM120, an antagonist antibody targeting GFRAL, in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II development for geographic atrophy; and NGM707, a dual antagonist monoclonal antibody (targeting immunoglobulin-like transcript 2/4) in Phase I/II trials for patients with advanced solid tumors. Additionally, the company is developing NGM831 and NGM438, both intended for the treatment of advanced solid tumors. NGM has established significant partnerships, including research, product development, and licensing agreements with Merck Sharp & Dohme Corp. A separate collaboration with Merck & Co., Inc. is dedicated primarily to creating new treatments for pressing unmet patient needs in retinal and cardiovascular-metabolic (CVM) diseases, such as heart failure. Established in 2007, NGM Biopharmaceuticals, Inc. maintains its corporate headquarters in South San Francisco, California.

CEO: David J. Woodhouse
IPO Date: Apr 4, 2019

Market Data

Open: $1.56
High: $1.57
Low: $1.54
Volume: 2.2M
Avg Volume: 969.9K
52W High: $4.69
52W Low: $0.6002

Valuation

Market Cap: $128.5M
Enterprise Value: $69.7M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$133.5M
Revenue: $4.4M
Net Income: -$142.4M
Cash: $58.8M
Debt: $0

Events

EarningsMay 2

EPS est. -0.46 · actual -0.58